Trials / Not Yet Recruiting
Not Yet RecruitingNCT07460245
Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma:AVESEC Trial - AVESEC Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study represents an innovative opportunity in the treatment of metastatic urothelial carcinoma
Detailed description
Phase II, multicenter, randomized, open-label, efficacy and safety study of maintenance avelumab compared to BSC in advanced or metastatic urothelial carcinoma patients not progressed on second-line platinum-based chemotherapy (carboplatin or cisplatin plus gemcitabine) pretreated with pembrolizumab plus enfortumab vedotin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab 800 mg flat-dose IV | Avelumab 800 mg flat-dose IV every 2 weeks |
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2026-06-01
- Completion
- 2030-12-01
- First posted
- 2026-03-10
- Last updated
- 2026-03-10
Locations
19 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT07460245. Inclusion in this directory is not an endorsement.